ARID1A-Deficient Tumors Acquire Immunogenic Neoantigens during the Development of Resistance to Targeted Therapy

ARID1A型 威罗菲尼 免疫原性 癌症研究 免疫疗法 免疫检查点 黑色素瘤 医学 靶向治疗 免疫系统 免疫学 癌症 生物 突变 内科学 转移性黑色素瘤 基因 生物化学
作者
Masahiro Okada,Satoru Yamasaki,Hiroshi Nakazato,Yuhya Hirahara,Takuya Ishibashi,Masami Kawamura,Kanako Shimizu,Shin‐ichiro Fujii
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:84 (17): 2792-2805 被引量:7
标识
DOI:10.1158/0008-5472.can-23-2846
摘要

Neoantigen-based immunotherapy is an attractive potential treatment for previously intractable tumors. To effectively broaden the application of this approach, stringent biomarkers are crucial to identify responsive patients. ARID1A, a frequently mutated subunit of SWI/SNF chromatin remodeling complex, has been reported to determine tumor immunogenicity in some cohorts; however, mutations and deletions of ARID1A are not always linked to clinical responses to immunotherapy. In this study, we investigated immunotherapeutic responses based on ARID1A status in targeted therapy-resistant cancers. Mouse and human BRAFV600E melanomas with or without ARID1A expression were transformed into resistant to vemurafenib, an FDA-approved specific BRAFV600E inhibitor. Anti-PD-1 antibody treatment enhanced antitumor immune responses in vemurafenib-resistant ARID1A-deficient tumors but not in ARID1A-intact tumors or vemurafenib-sensitive ARID1A-deficient tumors. Neoantigens derived from accumulated somatic mutations during vemurafenib resistance were highly expressed in ARID1A-deficient tumors and promoted tumor immunogenicity. Furthermore, the newly generated neoantigens could be utilized as immunotherapeutic targets by vaccines. Finally, targeted therapy resistance-specific neoantigen in experimental human melanoma cells lacking ARID1A were validated to elicit T-cell receptor responses. Collectively, the classification of ARID1A-mutated tumors based on vemurafenib resistance as an additional indicator of immunotherapy response will enable a more accurate prediction to guide cancer treatment. Furthermore, the neoantigens that emerge with therapy resistance can be promising therapeutic targets for refractory tumors. Significance: Chemotherapy resistance promotes the acquisition of immunogenic neoantigens in ARID1A-deficient tumors that confer sensitivity to immune checkpoint blockade and can be utilized for developing antitumor vaccines, providing strategies to improve immunotherapy efficacy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
gkads完成签到,获得积分10
1秒前
1秒前
隐形曼青的应助被好名采纳,获得10
1秒前
1秒前
yanhong发布了新的文献求助10
2秒前
CipherSage的应助被qiu采纳,获得10
3秒前
SciGPT的应助被开心德地采纳,获得10
3秒前
Ava的应助被XR采纳,获得10
4秒前
大模型的应助被zzyyqq采纳,获得10
5秒前
5秒前
chen完成签到,获得积分10
7秒前
我是老大的应助被开心德地采纳,获得10
9秒前
aypzx完成签到,获得积分10
10秒前
比目鱼完成签到 ,获得积分10
11秒前
11秒前
顾矜的应助被小D采纳,获得10
12秒前
艾格的应助被zzyyqq采纳,获得30
14秒前
科研通AI6.2的应助被大气幻柏采纳,获得10
15秒前
15秒前
15秒前
CodeCraft的应助被开心德地采纳,获得10
16秒前
好名发布了新的文献求助10
16秒前
17秒前
科目三的应助被yanhong采纳,获得10
18秒前
杜松子完成签到,获得积分10
18秒前
19秒前
情怀的应助被危机的小蚂蚁采纳,获得10
20秒前
打打的应助被能干的人采纳,获得30
20秒前
duotianzhiyi完成签到,获得积分10
20秒前
怡然的复天完成签到,获得积分10
21秒前
21秒前
Hannipham完成签到,获得积分10
21秒前
上官若男的应助被开心德地采纳,获得10
22秒前
司空博涛完成签到,获得积分20
22秒前
24秒前
24秒前
洁净雅彤完成签到,获得积分10
24秒前
满意的天思完成签到 ,获得积分10
25秒前
26秒前
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188371
求助须知:如何正确求助?哪些是违规求助? 9576179
关于积分的说明 21845965
捐赠科研通 7786421
什么是DOI,文献DOI怎么找? 3435292
关于科研通互助平台的介绍 2559601
邀请新用户注册赠送积分活动 2482276